Introduction: Primary intestinal lymphangiectasia (PIL) is a very rare disorder usually diagnosed before the third year of life or later in adulthood, presenting with pitting edema, hypoproteinemia and low immunoglobulin levels. The location and the extent of the affected bowel greatly influence the clinical manifestation. The localized or segmental form of PIL is extremely rare with only five pediatric cases reported worldwide.

Case Presentation: A 10 year-old Caucasian boy presented with 3 months history of recurrent abdominal pain and a 1 month history of diarrhea. An ultrasound scan was performed on two separate occasions 10 days apart, revealing a growing cystic mass on the right side of the abdomen, in front of the psoas muscle. Subsequently an MRI scan confirmed that the mass originated from the mesenteries and infiltrates a short segment of the small bowel. Surgical resection of the affected segment was performed. Histopathological examination of the removed segment of ileum was consistent with intestinal lymphangiectasia. We could not identify any associated genetic syndromes or any other conditions that could have caused secondary intestinal lymphangiectasia. The patient's recovery from surgery was uneventful and no recurrence was observed in the following 4 years.

Conclusion: Despite being a benign condition, mortality of PIL can be as high as 13% due to the difficulties associated with the management of the disease. PIL should be considered as a rare but potential cause for an abdominal mass, even in the older child, when cystic mesenterial involvement might be seen on ultrasound or MRI. In selected cases of PIL affecting only a short segment of the bowel or following unsuccessful conservative treatment, surgical resection of the affected bowel segment can be curative.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6375111PMC
http://dx.doi.org/10.2147/IMCRJ.S192940DOI Listing

Publication Analysis

Top Keywords

intestinal lymphangiectasia
16
short segment
8
surgical resection
8
pil
5
segment
5
pediatric localized
4
intestinal
4
localized intestinal
4
lymphangiectasia
4
lymphangiectasia treated
4

Similar Publications

Lymphangiogram in primary intestinal lymphangiectasia.

Indian J Gastroenterol

January 2025

Department of Gastroenterology and Hepatology, Kasturba Medical College, Manipal Academy of Higher Education, Manipal, 576 104, India.

View Article and Find Full Text PDF

Effects of corn oil ingestion on the intestinal mucosa of normal dogs.

Front Vet Sci

December 2024

Institute of Animal Medicine, College of Veterinary Medicine, Gyeongsang National University, Jinju, Republic of Korea.

Introduction: We assessed corn oil's oral effectiveness in detecting small bowel changes in healthy dogs through ultrasonography, endoscopy, and histopathology. We hypothesize that corn oil ingestion will not significantly increase the visibility of lymphatics and lacteals in healthy dogs.

Methods: Five healthy male beagles were studied under institutional guidelines.

View Article and Find Full Text PDF

Case 332: Tyrosine Kinase Inhibitor-induced Intestinal Lymphangiectasia.

Radiology

December 2024

From the Department of Radiology, Mayo Clinic Arizona, 5777 E Mayo Blvd, Phoenix, AZ 85054.

History A 65-year-old male patient with a history of sarcomatoid renal cell carcinoma and prior right nephrectomy developed recurrent disease adjacent to the inferior vena cava. The patient underwent surveillance imaging 7 months after initiation of treatment with maximum-dose pazopanib and less than 1 month after completing a 2-month regimen of palliative stereotactic body radiation therapy to the right nephrectomy bed and site of recurrence. (Stereotactic body radiation therapy was initiated 5 months after pazopanib treatment was initiated.

View Article and Find Full Text PDF

An evaluation of pozelimab for the treatment of CHAPLE disease.

Expert Opin Biol Ther

January 2025

Division of Allergy and Immunology, Department of Pediatrics, School of Medicine, Marmara University, Istanbul, Turkey.

Introduction: CHAPLE disease is a severe, ultra-rare disorder caused by CD55 gene mutations, leading to uncontrolled complement hyperactivation, protein-losing enteropathy, and systemic thrombosis. Recent advances in targeted therapies, particularly the C5 inhibitor pozelimab (Veopoz), offer new treatment options by addressing complement dysregulation, marking a shift from symptomatic to precision therapy.

Areas Covered: This review explores the pathophysiology, clinical manifestations, and current treatments for CHAPLE disease.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!